Sugi Predict

Sugi Predict / Targets / ATF1

ATF1

Cyclic AMP-dependent transcription factor ATF-1 · P18846 · ATF1 on Sugi Atlas →

2,051 patent compounds predicted against ATF1, 764 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL6977551 SCHEMBL6977551 0.62 16/20
SCHEMBL15290081 SCHEMBL15290081 0.56 15/20
SCHEMBL15273207 SCHEMBL15273207 0.54 15/20
SCHEMBL14138893 SCHEMBL14138893 0.53 15/20
SCHEMBL8398500 SCHEMBL8398500 0.53 15/20
SCHEMBL13077675 SCHEMBL13077675 0.67 14/20
SCHEMBL1549128 SCHEMBL1549128 0.62 14/20
SCHEMBL1859795 SCHEMBL1859795 0.60 14/20
SCHEMBL14117904 SCHEMBL14117904 0.60 14/20
SCHEMBL7489466 SCHEMBL7489466 0.59 14/20
SCHEMBL2307377 SCHEMBL2307377 0.61 13/20
SCHEMBL79014 SCHEMBL79014 0.60 13/20
SCHEMBL9564861 SCHEMBL9564861 0.58 13/20
SCHEMBL1860264 SCHEMBL1860264 0.58 13/20
SCHEMBL9564875 SCHEMBL9564875 0.57 13/20
SCHEMBL1821585 SCHEMBL1821585 0.57 13/20
SCHEMBL8281060 SCHEMBL8281060 0.52 13/20
SCHEMBL1862523 SCHEMBL1862523 0.74 12/20
SCHEMBL13077672 SCHEMBL13077672 0.65 12/20
SCHEMBL8518174 SCHEMBL8518174 0.62 12/20

Clinical trials — most relevant to ATF1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity PHASE4COMPLETED
Does Aldosterone Cause Hypertension by a Non-Renal Mechanism? PHASE4UNKNOWN
Clinical Evaluation of the Effect of Metformin in Sepsis PHASE3UNKNOWN
The Use of Inhaled Corticosteroids in the Treatment of Asthma is Children in the Emergency Room PHASE2/PHASE3COMPLETED
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant PHASE1/PHASE2RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19 PHASE2UNKNOWN
Metformin for Fibromyalgia Symptoms (INFORM Trial) PHASE2RECRUITING
Safety and Feasibility of Metformin for Sepsis Induced AKI PHASE2COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Rosiglitazone to Reverse Metabolic Defects in Diabetes PHASE2COMPLETED
Rapid Antidepressant Effects of Yohimbine in Major Depression PHASE2COMPLETED
Blood Flow Restriction Training in Chronic Heart Failure: an Effective Training Strategy? PHASE2COMPLETED
Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy PHASE2RECRUITING
Post-Cardiac Surgery Acute Kidney Injury Prevention by Administration of Proton Pump Inhibitor (P2 Trial) PHASE2RECRUITING
The NaBu Effect on Menstruation in Women nanRECRUITING
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder. nanCOMPLETED
Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis nanNOT_YET_RECRUITING
Quantification of GADD34 Expression in RA nanCOMPLETED
Immune Interactions in Severe Asthma nanCOMPLETED
Pituitary Derived-Intermedin is an Estrogen-Modulated Factor for Reducing Blood Pressure nanUNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Relationship Between Obesity and Periodontal Disease nanCOMPLETED
Nasturtium (Tropaeolum Majus L) Intake and Biochemical Parameters in Pre-diabetic Subjects in Bogota Colombia nanCOMPLETED
Nutraceutical Composition Containing Natural Products Derivatives on the Modulation of the Endocrine Neuroimmune Axis nanCOMPLETED
Evaluation of the Predictive Effect of Inflammatory Markers in MI Patients nanUNKNOWN
Inflammation Severity and miRNA-126 in Trauma nanRECRUITING
Pigeon Peas (Cajanus Cajan) : a Natural Anti-inflammatory Facilitating Weight Loss in Obese Patients Returning to Sport? nanUNKNOWN
Effect of Age on Glucose and Lipid Metabolism nanCOMPLETED
Tecfidera Diffusion Tensor Imaging nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ATF1 binder may also engage these)

ProteinNameSimilarity
Q08DA8 — 1.000 Q08DA8 →
Q03061 — 1.000 Q03061 →
P81269 — 1.000 P81269 →
Q01147 — 1.000 Q01147 →
CREB1 Cyclic AMP-responsive element-binding protein 1 1.000 landscape →
P15337 — 1.000 P15337 →
P27925 — 1.000 P27925 →
P27699 — 0.999 P27699 →
Q1LZH5 — 0.998 Q1LZH5 →
Q03060 — 0.998 Q03060 →
P79145 — 0.997 P79145 →
Q4VYS1 — 0.996 Q4VYS1 →
Q5QL03 — 0.996 Q5QL03 →
P0CF24 — 0.996 P0CF24 →
O70477 — 0.995 O70477 →
P55347 — 0.995 P55347 →
P40645 — 0.995 P40645 →
Q2HJ84 — 0.994 Q2HJ84 →
Q8HZ00 — 0.994 Q8HZ00 →
Q8TAK5 — 0.994 Q8TAK5 →
Q5RCU4 — 0.994 Q5RCU4 →
P23899 — 0.994 P23899 →
Q498D1 — 0.994 Q498D1 →
Q2LE08 — 0.994 Q2LE08 →
G5ECU7 — 0.993 G5ECU7 →
Q0P5K4 — 0.993 Q0P5K4 →
P35680 — 0.993 P35680 →
Q5W1J5 — 0.993 Q5W1J5 →
Q5R6A9 — 0.993 Q5R6A9 →
Q21361 — 0.993 Q21361 →